Park Paul, Chang Victor, Yeh Hsueh-Han, Schwalb Jason M, Nerenz David R, Schultz Lonni R, Abdulhak Muwaffak M, Easton Richard, Perez-Cruet Miguelangelo, Kashlan Osama N, Oppenlander Mark E, Szerlip Nicholas J, Swong Kevin N, Aleem Ilyas S
Departments of1Neurosurgery and.
2Department of Neurosurgery, Henry Ford Hospital, Detroit.
J Neurosurg Spine. 2020 Dec 11;34(3):531-536. doi: 10.3171/2020.7.SPINE20729. Print 2021 Mar 1.
In 2017, Michigan passed new legislation designed to reduce opioid abuse. This study evaluated the impact of these new restrictive laws on preoperative narcotic use, short-term outcomes, and readmission rates after spinal surgery.
Patient data from 1 year before and 1 year after initiation of the new opioid laws (beginning July 1, 2018) were queried from the Michigan Spine Surgery Improvement Collaborative database. Before and after implementation of the major elements of the new laws, 12,325 and 11,988 patients, respectively, were treated.
Patients before and after passage of the opioid laws had generally similar demographic and surgical characteristics. Notably, after passage of the opioid laws, the number of patients taking daily narcotics preoperatively decreased from 3783 (48.7%) to 2698 (39.7%; p < 0.0001). Three months postoperatively, there were no differences in minimum clinically important difference (56.0% vs 58.0%, p = 0.1068), numeric rating scale (NRS) score of back pain (3.5 vs 3.4, p = 0.1156), NRS score of leg pain (2.7 vs 2.7, p = 0.3595), satisfaction (84.4% vs 84.7%, p = 0.6852), or 90-day readmission rate (5.8% vs 6.2%, p = 0.3202) between groups. Although there was no difference in readmission rates, pain as a reason for readmission was marginally more common (0.86% vs 1.22%, p = 0.0323).
There was a meaningful decrease in preoperative narcotic use, but notably there was no apparent negative impact on postoperative recovery, patient satisfaction, or short-term outcomes after spinal surgery despite more restrictive opioid prescribing. Although the readmission rate did not significantly increase, pain as a reason for readmission was marginally more frequently observed.
2017年,密歇根州通过了旨在减少阿片类药物滥用的新立法。本研究评估了这些新的限制性法律对脊柱手术前麻醉药物使用、短期结局和再入院率的影响。
从密歇根脊柱手术改善协作数据库中查询新阿片类药物法实施前1年和实施后1年(从2018年7月1日开始)的患者数据。新法律主要内容实施前后,分别有12325例和11988例患者接受了治疗。
阿片类药物法通过前后的患者在人口统计学和手术特征方面总体相似。值得注意的是,阿片类药物法通过后,术前每日服用麻醉药物的患者数量从3783例(48.7%)降至2698例(39.7%;p<0.0001)。术后3个月,两组之间在最小临床重要差异(56.0%对58.0%,p=0.1068)、背痛数字评分量表(NRS)评分(3.5对3.4,p=0.1156)、腿痛NRS评分(2.7对2.7,p=0.3595)、满意度(84.4%对84.7%,p=0.6852)或90天再入院率(5.8%对6.2%,p=0.3202)方面均无差异。尽管再入院率没有差异,但因疼痛导致的再入院在边缘上更为常见(0.86%对1.22%,p=0.0323)。
术前麻醉药物使用有显著减少,但值得注意的是,尽管阿片类药物处方更加严格,但对脊柱手术后的恢复、患者满意度或短期结局没有明显负面影响。虽然再入院率没有显著增加,但因疼痛导致的再入院在边缘上观察到的频率更高。